文献速递关节外科

因子V Leiden患者全髋关节置换术:风险升高仅限于静脉血栓栓塞事件

Total Hip Arthroplasty in Patients Who Have Factor V Leiden: Elevated Risks Isolated to Venous Thromboembolism Events.
PubMed 文献 · J Arthroplasty · 2024-06-03

基于行政索赔数据库纳入2010年至2021年10月因骨关节炎行初次全髋关节置换术的544022例成人患者,其中因子V Leiden(FVL)1138例(0.21%),按年龄、性别和Elixhauser合并症指数1:4匹配(FVL组1131例,非FVL组4519例)。多变量分析显示FVL患者90天深静脉血栓(OR=9.20)、肺栓塞(OR=6.89)及聚合严重不良事件(OR=4.74)和全部不良事件(OR=1.98)风险升高,但其他围手术期不良事件或5年再手术风险未升高。更强效的化学预防药物(华法林、肝素、直接口服抗凝药)降低但未完全消除升高的VTE风险,且未增加出血事件。

要点

  • FVL患者行THA后90天DVT风险OR=9.20,PE风险OR=6.89。
  • FVL患者聚合严重不良事件OR=4.74,全部不良事件OR=1.98。
  • 华法林、肝素或DOAC降低但未完全消除VTE风险,未增加出血。

核心结论

  • 本研究量化了FVL患者行THA相关的显著升高的VTE风险。
  • 其他特定不良事件和5年再手术无差异令人放心。
  • 化学预防药物在该人群中重要,可能需要进一步关注。

研究设计与样本

  • 行政索赔数据库识别2010年至2021年10月因骨关节炎指征行初次THA的544022例成人患者。
  • FVL患者1138例(0.21%),按年龄、性别和Elixhauser合并症指数1:4匹配,FVL组1131例,非FVL组4519例。
  • 采用单变量和多变量分析评估90天并发症,log-rank检验比较5年假体生存率,并评估化学预防药物使用。

主要发现

  • 多变量分析显示FVL患者90天深静脉血栓OR=9.20,肺栓塞OR=6.89。
  • FVL患者聚合严重不良事件OR=4.74,全部不良事件OR=1.98。
  • FVL患者其他围手术期不良事件或5年再手术风险未升高。
  • 华法林、肝素或DOAC降低但未完全消除升高的VTE风险,且未增加出血事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total hip arthroplasty (THA) is a common procedure that requires consideration of preexisting comorbidities. Factor V Leiden (FVL), an inherited thrombophilia, is one such condition that predisposes patients to venous thromboembolism (VTE, deep vein thrombosis, and pulmonary embolism). The present study aimed to characterize the risks associated with FVL patients undergoing THA and evaluate the effect of VTE chemoprophylactic agents on these risks. METHODS: A total of 544,022 adult patients who underwent primary THA for osteoarthritis indications between 2010 and October 2021 were identified in an administrative claims database. Of these, FVL was identified in 1,138 (0.21%). Patients who had and did not have FVL were matched at a 1:4 ratio (1,131 with FVL and 4,519 without FVL) based on age, sex, and Elixhauser comorbidity index. Univariable and multivariable analyses were assessed for 90-day complications. Implant survival at 5 years was assessed and compared with log-rank tests. The relative use of different chemoprophylactic agents, including aspirin, warfarin, heparin, or direct oral anticoagulant (DOAC), was assessed. Bleeding events and VTE were compared for those prescribed either aspirin or warfarin, heparin, or DOAC. A Bonferroni correction was applied. RESULTS: On multivariable analysis, FVL patients were found to have increased odds of 90-day deep vein thrombosis (odds ratio (OR) = 9.20), pulmonary embolism (OR = 6.89), and aggregated severe and all adverse events (OR = 4.74 and 1.98, respectively), but not elevated risk of other perioperative adverse events or 5-year reoperations. More potent chemoprophylactic agents (warfarin, heparin, DOAC) reduced, but did not completely eliminate, the increased VTE risks (without increasing bleeding events). CONCLUSIONS: This study quantified the significantly elevated VTE risk associated with FVL patients undergoing THA. The lack of difference in other specific adverse events and 5-year reoperations is reassuring. Clearly, chemoprophylactic agents are important in this population and may need further attention.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Sanchez JG, Jiang WM, Dhodapkar MM, et al. Total Hip Arthroplasty in Patients Who Have Factor V Leiden: Elevated Risks Isolated to Venous Thromboembolism Events. J Arthroplasty. 2024. PMID: 38838962. doi:10.1016/j.arth.2024.05.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。